The FDA is investigating the death last month of an eight-year-old boy in Brazil who had received Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl)—though the company and its ...

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

Barclays downgraded Sarepta (SRPT) to Underweight from Equal Weight with a price target of $10, down from $18. The firm says the suspension of ...

The Fed is expected to keep rates steady, but Powell will get questions on Fed independence. Apple, Microsoft, Meta and ...